Human CD40 Ligand (CD40L)

<strong> Human CD40 Ligand (CD40L)</strong>_x000D_ <strong>Catalog number:</strong> B2018539_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> ~16 kDa_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> CD40L_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond Adv Drug Deliv Rev. 2019 Feb 15;141:92-103._x000D_ 2: Ots HD, Tracz JA, Vinokuroff KE, Musto AE. CD40-CD40L in Neurological Disease Int J Mol Sci. 2022 Apr 8;23(8):4115._x000D_ 3: Leite LFB, Máximo TA, Mosca T, Forte WCN. CD40 Ligand Deficiency Allergol Immunopathol (Madr). 2020 Jul-Aug;48(4):409-413._x000D_ 4: Zhang Y, Hou X, Du S, Xue Y, Yan J, Kang DD, Zhong Y, Wang C, Deng B, McComb DW, Dong Y. Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy Nat Nanotechnol. 2023 Nov;18(11):1364-1374._x000D_ 5: Angelou A, Antoniou E, Garmpis N, Damaskos C, Theocharis S, Margonis GA. The Role of Soluble CD40L Ligand in Human Carcinogenesis Anticancer Res. 2018 May;38(5):3199-3201._x000D_ 6: Ma X, Chen C, Fang L, Zhong X, Chang Y, Li R, Wang Y, Hu X, Qiu W, Shu Y. Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis J Neuroimmunol. 2022 Jan 15;362:577762._x000D_ 7: Choi H, Lee HJ, Sohn HJ, Kim TG. CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8(+) T cells BMC Immunol. 2023 Jun 30;24(1):15._x000D_ 8: Ceglia V, Zurawski S, Montes M, Bouteau A, Wang Z, Ellis J, Igyártó BZ, Lévy Y, Zurawski G. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties J Immunol. 2021 Oct 15;207(8):2060-2076._x000D_ 9: Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis Trends Cardiovasc Med. 2002 Jan;12(1):27-32._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32222950">10: Bosmans LA, Bosch L, Kusters PJH, Lutgens E, Seijkens TTP. The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease J Cardiovasc Transl Res. 2021 Feb;14(1):13-22. </a>_x000D_ _x000D_ <strong>Products Related to Human CD40 Ligand (CD40L) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>